An independent reference library on stem cell therapy and cancer immunotherapy — clinical research, mechanisms, and industry developments.
Step 1 — Topic
Step 2 — Category
Small human studies of adipose-derived and placental stem cells show shrinking plaques and less distress in Peyronie's disease, but the best trial missed its curvature goal and nothing is FDA-approved.
7 min readBy RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Lab studies and a small case series suggest mesenchymal stem cells may calm hidradenitis suppurativa inflammation and help stubborn tunnels heal — but the approach is experimental and not FDA-approved.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Stem cell therapies move through a funding relay — NIH and state grants, universities, foundations, then venture capital. Legitimate trials don't charge patients for the experimental product.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
The FDA's 2024 class-wide boxed warning on secondary T-cell cancers after CAR-T flagged a real signal — but the largest datasets since show the absolute risk is low and CAR-T's benefits still outweigh it.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Most pancreatic tumors are genetically quiet and walled off by dense stroma, so checkpoint inhibitors rarely work — except in the small MSI-H/dMMR subset. Personalized mRNA vaccines are the most promising lead.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Randomized trials of fat-derived stem cell injections into the jaw joint beat hyaluronic acid on pain and mouth opening — but the evidence base is small and rated weak.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Mesenchymal stem cells and their vesicles reduce liver fat and fibrosis in animal models — but there is still no completed human trial in NAFLD or NASH specifically.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
